Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)

Impaired Fasting Glucose Is the Major Determinant of the 20‐Year Mortality Risk Associated With Metabolic Syndrome in Nondiabetic Patients With Stable Coronary Artery Disease

“…The design and rationale of the BIP Registry and study were published previously 25, 26. Of the 15 524 screened patients, only 3090 (20%) were randomized in the prospective interventional 6‐year BIP study that compared bezafibrate with placebo.…”

Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients

“…The design and rationale of the BIP study have been published previously. 9,10 The BIP registry patients had a diagnosis of CHD established by: (1) a history of myocardial infarction (MI) occurring no less than 6 months but no longer than 5 years prior to enrollment; (2) stable angina pectoris, which was symptomatic and documented on nuclear study/exercise test/coronary angiography (demonstrating a stenosis of above or equal to 60 % in one of the major coronary arteries); (3) primary transcutaneous coronary angioplasty (PTCA) or coronary artery bypass graft surgery (CABG) operation in the 6 months prior to enrollment.…”

Long-term diuretic therapy in patients with coronary disease: increased colon cancer-related mortality over a 5-year follow-up

“…13 The BIP study was designed and initiated in 1990. There was no difference in the distribution of all-cause and cardiac mortality between the bezafibrate and placebo study groups.…”

“…14 The major inclusion and exclusion criteria for the BIP study, as well as the ethical guidelines, have been previously reported. 13,14 In brief, between 1 February 1990, and 30 October 1992 all patients underwent a complete medical examination and biochemical blood tests; historical, medical, and drug intake data were recorded. The major exclusion criteria for the BIP study were: permanent pacemaker implantation, cerebrovascular disease, chronic hepatic or renal disease, peripheral vascular disease, malignant diseases, estrogen replacement therapy and insulin dependent diabetes mellitus.…”